This finding suggests that aberrant regulation of the ALKAL2, ALK, and MYCN troika in neuroblastoma, for example in 2p-gain, may drive ALK signaling activity and therefore could benefit from ALK TKI treatment. This evidence concerns the gene MYCN and neuroblastoma.